708 related articles for article (PubMed ID: 30587928)
1. Tocilizumab in the treatment of rheumatoid arthritis: an evidence-based review and patient selection.
Biggioggero M; Crotti C; Becciolini A; Favalli EG
Drug Des Devel Ther; 2019; 13():57-70. PubMed ID: 30587928
[TBL] [Abstract][Full Text] [Related]
2. Profile of sarilumab and its potential in the treatment of rheumatoid arthritis.
Raimondo MG; Biggioggero M; Crotti C; Becciolini A; Favalli EG
Drug Des Devel Ther; 2017; 11():1593-1603. PubMed ID: 28579757
[TBL] [Abstract][Full Text] [Related]
3. [Tocilizumab in rheumatoid arthritis].
Rueda Gotor J; Blanco Alonso R
Reumatol Clin; 2011 Mar; 6S3():S29-32. PubMed ID: 21794769
[TBL] [Abstract][Full Text] [Related]
4. Tocilizumab for treating rheumatoid arthritis: an evaluation of pharmacokinetics/pharmacodynamics and clinical efficacy.
Song SN; Yoshizaki K
Expert Opin Drug Metab Toxicol; 2015 Feb; 11(2):307-16. PubMed ID: 25491492
[TBL] [Abstract][Full Text] [Related]
5. Safety of subcutaneous versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
McLaughlin M; Östör A
Expert Opin Drug Saf; 2015 Mar; 14(3):429-37. PubMed ID: 25553607
[TBL] [Abstract][Full Text] [Related]
6. Subcutaneous tocilizumab for the treatment of rheumatoid arthritis.
Mitchell E; Jones G
Expert Rev Clin Immunol; 2016; 12(2):103-14. PubMed ID: 26629984
[TBL] [Abstract][Full Text] [Related]
7. Antiarrhythmic potential of anticytokine therapy in rheumatoid arthritis: tocilizumab reduces corrected QT interval by controlling systemic inflammation.
Lazzerini PE; Acampa M; Capecchi PL; Fineschi I; Selvi E; Moscadelli V; Zimbone S; Gentile D; Galeazzi M; Laghi-Pasini F
Arthritis Care Res (Hoboken); 2015 Mar; 67(3):332-9. PubMed ID: 25186226
[TBL] [Abstract][Full Text] [Related]
8. Tocilizumab, a humanized anti-IL-6R antibody, as an emerging therapeutic option for rheumatoid arthritis: molecular and cellular mechanistic insights.
Hashizume M; Tan SL; Takano J; Ohsawa K; Hasada I; Hanasaki A; Ito I; Mihara M; Nishida K
Int Rev Immunol; 2015 May; 34(3):265-79. PubMed ID: 25099958
[TBL] [Abstract][Full Text] [Related]
9. Tocilizumab in the treatment of adult rheumatoid arthritis.
Sanmartí R; Ruiz-Esquide V; Bastida C; Soy D
Immunotherapy; 2018 Mar; 10(6):447-464. PubMed ID: 29495891
[TBL] [Abstract][Full Text] [Related]
10. Tocilizumab in the treatment of rheumatoid arthritis and beyond.
Shetty A; Hanson R; Korsten P; Shawagfeh M; Arami S; Volkov S; Vila O; Swedler W; Shunaigat AN; Smadi S; Sawaqed R; Perkins D; Shahrara S; Sweiss NJ
Drug Des Devel Ther; 2014; 8():349-64. PubMed ID: 24729685
[TBL] [Abstract][Full Text] [Related]
11. A novel scoring system based on common laboratory tests predicts the efficacy of TNF-inhibitor and IL-6 targeted therapy in patients with rheumatoid arthritis: a retrospective, multicenter observational study.
Nakagawa J; Koyama Y; Kawakami A; Ueki Y; Tsukamoto H; Horiuchi T; Nagano S; Uchino A; Ota T; Akahoshi M; Akashi K
Arthritis Res Ther; 2017 Aug; 19(1):185. PubMed ID: 28800780
[TBL] [Abstract][Full Text] [Related]
12. Rheumatoid arthritis: new monoclonal antibodies.
Serio I; Tovoli F
Drugs Today (Barc); 2018 Mar; 54(3):219-230. PubMed ID: 29771256
[TBL] [Abstract][Full Text] [Related]
13. Serum interleukin 6 before and after therapy with tocilizumab is a principal biomarker in patients with rheumatoid arthritis.
Shimamoto K; Ito T; Ozaki Y; Amuro H; Tanaka A; Nishizawa T; Son Y; Inaba M; Nomura S
J Rheumatol; 2013 Jul; 40(7):1074-81. PubMed ID: 23637318
[TBL] [Abstract][Full Text] [Related]
14. Factors influencing the choice of first- and second-line biologic therapy for the treatment of rheumatoid arthritis: real-life data from the Italian LORHEN Registry.
Monti S; Klersy C; Gorla R; Sarzi-Puttini P; Atzeni F; Pellerito R; Fusaro E; Paolazzi G; Rocchetta PA; Favalli EG; Marchesoni A; Caporali R
Clin Rheumatol; 2017 Apr; 36(4):753-761. PubMed ID: 28058538
[TBL] [Abstract][Full Text] [Related]
15. Subcutaneous Tocilizumab Is Effective for Treatment of Elderly-Onset Rheumatoid Arthritis.
Kondo N; Fujisawa J; Endo N
Tohoku J Exp Med; 2020 May; 251(1):9-18. PubMed ID: 32404541
[TBL] [Abstract][Full Text] [Related]
16. Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: Evaluation of an antidrug antibody ELISA using clinical adverse event-driven immunogenicity testing.
Stubenrauch K; Wessels U; Birnboeck H; Ramirez F; Jahreis A; Schleypen J
Clin Ther; 2010 Aug; 32(9):1597-609. PubMed ID: 20974317
[TBL] [Abstract][Full Text] [Related]
17. High levels of natural killer cells are associated with response to tocilizumab in patients with severe rheumatoid arthritis.
Daïen CI; Gailhac S; Audo R; Mura T; Hahne M; Combe B; Morel J
Rheumatology (Oxford); 2015 Apr; 54(4):601-8. PubMed ID: 25231180
[TBL] [Abstract][Full Text] [Related]
18. Targeting IL-6 or IL-6 Receptor in Rheumatoid Arthritis: What's the Difference?
Avci AB; Feist E; Burmester GR
BioDrugs; 2018 Dec; 32(6):531-546. PubMed ID: 30488231
[TBL] [Abstract][Full Text] [Related]
19. IL-6 inhibition for the treatment of rheumatoid arthritis and other conditions.
Woodrick RS; Ruderman EM
Bull NYU Hosp Jt Dis; 2012; 70(3):195-9. PubMed ID: 23259628
[TBL] [Abstract][Full Text] [Related]
20. A new bioassay for measuring the strength of IL-6/STAT3 signal inhibition by tocilizumab in patients with rheumatoid arthritis.
Saito S; Suzuki K; Yoshimoto K; Kaneko Y; Matsumoto Y; Yamaoka K; Takeuchi T
Arthritis Res Ther; 2017 Oct; 19(1):231. PubMed ID: 29041951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
